HudsonAlpha Awarded $100k Grant
News Oct 15, 2015
“The Jane K. Lowe Charitable Foundation is excited that our grant will assist HudsonAlpha to bring genomic medicine to our region and to become a leader in this rapidly developing technology,” said Jane K. Lowe board member John Wynn. “During her lifetime, Mrs. Lowe was a generous supporter of medical research. This grant enables our foundation to carry on Mrs. Lowe’s legacy by supporting this innovative approach to patient care.
HudsonAlpha recently recruited five world-renowned faculty investigators specializing in genomic medicine. This November, the Institute will open the world’s first clinic solely for the practice of genomic medicine. HudsonAlpha has also established a fully accredited and certified Clinical Sequencing Laboratory, which can provide clinically-validated and interpreted genomic information for physicians worldwide.
”These funds from the Jane Knight Lowe Foundation help HudsonAlpha welcome five of the world’s best genomic scientists. Working with our existing faculty, they are literally changing medicine,” said Lynne Berry, vice president for advancement at HudsonAlpha.
“From the beginning, the mission of HudsonAlpha’s mission has been to utilize the power of genomics to help improve lives. I can’t think of a better way to do that than to use what we know about the genomic sequence to identify the causes of unknown diseases and help identify new therapies for some of the sickest patients,” said Richard M. Myers, PhD, president and scientific director of HudsonAlpha. “We are deeply grateful to the Jane K. Lowe Foundation for this gift.”
Minoryx Therapeutics spins off SEE-Tx platform into new company, Gain TherapeuticsNews
The new Swiss company will operate in Lugano and Barcelona under the scientific management of Minoryx co-founder Dr Xavier Barril.READ MORE
Evolution Threatens Efficient Bioproduction Scale-UpNews
The transition towards sustainable biobased chemical production is important for green growth, but productivity and yield of engineered cells frequently decrease in large industry-scale fermentation. According to a new study, the role of evolution has been underestimated in limiting bioprocesses.
Biomarkers Could Produce Preeclampsia Diagnostic TestNews
Small non-coding RNA analysis may revolutionize how doctors assess preeclampsia risk.READ MORE
Comments | 0 ADD COMMENT
World Advanced Therapies & Regenerative Medicine Congress
May 16 - May 18, 2018